These results support the concept that Bisindolylmaleimide IX may be useful to treat BCR-ABL positive leukemia, including CML that is resistant to Imatinib, nilotinib, and dasatinib. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.